医药板块今日集体回调，关注恒生创新药ETF（159316）、创新药ETF易方达（516080）等投资价值

Core Viewpoint - The pharmaceutical sector experienced a collective pullback today, with various indices reflecting declines, while the Hang Seng Innovation Drug ETF saw significant net subscriptions, indicating ongoing investor interest in the sector [1]. Group 1: Market Performance - The CSI 300 Pharmaceutical Health Index fell by 1.6% [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 1.3% [1] - The CSI Hong Kong Stock Connect Pharmaceutical Health Comprehensive Index and the CSI Innovative Drug Industry Index both dropped by 1.2% [1] - The CSI Biotechnology Theme Index declined by 1.1% [1] Group 2: Investment Trends - The Hang Seng Innovation Drug ETF (159316) recorded over 40 million net subscriptions throughout the day [1] - According to Wind data, the Hang Seng Innovation Drug ETF attracted nearly 1.2 billion yuan in investments this month, ranking first in the Hong Kong innovative drug sector [1] Group 3: Analyst Insights - China Galaxy Securities noted that the pharmaceutical sector has undergone a prolonged valuation adjustment, but a significant structural recovery trend has emerged recently [1] - The firm anticipates that the innovative drug business development (BD) will continue in the second half of the year, with a global trend of central banks lowering interest rates likely to further enhance the valuation of the innovative drug sector [1]